Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026)
Argenx Se (ARGX) posted quarterly Total Non-Current Liabilities of $40.0 million for Q2 2026, down 99.89% year-on-year from $37.9 billion in Q2 2025, and up 2.56% on a QoQ basis from $39.0 million in Q4 2025.
Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Total Non-Current Liabilities for 11 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 99.89% year-over-year to $40.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.0 million (down 99.89% YoY) and the FY2025 annual result came in at $39.0 million, up 13.63% from the prior year.
- Total Non-Current Liabilities grew to $40.0 million in Q2 2026 per ARGX's latest filing, from $39.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ARGX reached as high as $37.9 billion in Q2 2025 and fell as low as $14.4 million in Q2 2022.
- A 5-year average of $4.2 billion and a median of $34.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 109282.39% — and 2026, when it plunged 99.89%.
- Year by year, Total Non-Current Liabilities stood at $18.3 million in 2022, then grew by 20.09% to $22.0 million in 2023, then soared by 56.31% to $34.3 million in 2024, then rose by 13.63% to $39.0 million in 2025, then rose by 2.56% to $40.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.0 million, $39.0 million, and $37.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Dec 31, 2025 | 39.00 Mn |
| Jun 30, 2025 | 37.94 Bn |
| Dec 31, 2024 | 34.32 Mn |
| Jun 30, 2024 | 34.68 Mn |
| Dec 31, 2023 | 21.96 Mn |
| Jun 30, 2023 | 17.95 Mn |
| Dec 31, 2022 | 18.29 Mn |
| Jun 30, 2022 | 14.42 Mn |
| Dec 31, 2021 | 14.81 Mn |
| Jun 30, 2021 | 17.05 Mn |
| Dec 31, 2020 | 255.37 Mn |
| Jun 30, 2020 | 235.89 Mn |
| Dec 31, 2019 | 253.35 Mn |
| Jun 30, 2019 | 274.66 Mn |
| Dec 31, 2018 | 7,965.68 |
| Jun 30, 2018 | 36,080.24 |
| Dec 31, 2017 | 2.11 Mn |
| Jun 30, 2017 | 1,443.21 |
| Dec 31, 2016 | 14.53 Mn |